BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 18, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for Jan. 18, 2022

Jan. 18, 2022
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abacus Diagnostica, Allspire, Clinisys, GN Group, Horizon Lab Systems, Intermediq, Kaivogen, Kurin, Labrox, Menarini Diagnostics, MIPS, Nanalysis, Nugen, Quad Systems, Science 37, Shimadzu, Sonde Health, Sunquest Information Systems, Uniogen, Worldwide Clinical Trials.
Read More

In the clinic for Jan. 18, 2022

Jan. 18, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achiko, Angle, Biology Works, Moleculight, Neovasc.
Read More
COVID-19 vaccine vials on conveyor belt

US lawmakers urge government to become vaccine manufacturer

Jan. 18, 2022
By Mari Serebrov
Should the U.S. government be in the business of manufacturing COVID-19 vaccines? Several prominent Democratic senators and representatives would say yes.
Read More

Regulatory actions for Jan. 18, 2022

Jan. 18, 2022

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Algernon, Glenmark, Novartis, Numinus, Pfizer.


Read More

Other news to note for Jan. 18, 2022

Jan. 18, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Almirall, Amagma, Artizan, Bayer, Betterlife, Celmatix, Claritas, Cosette, Cybin, Cytoimmune, Daiichi Sankyo, Endo, Endosane, Eracal, Evelo, Evgen, Evotec, Feldan, Filament, Immuron, Innovent, IRB Barcelona, J&J, Kyowa Kirin, Lantern, Lava, Leyden, Merck & Co., Mindrank, Neurimmune, Novo Nordisk, Nrx, Ono, Poolbeg, Praxis, Ridgeback, Qualigen, Vanda, Virpax, Wesana.
Read More
Henley Ion Virus Defender device

New Orleans device firm reveals high hopes for COVID defense tech

Jan. 14, 2022
By Catherine Longworth
Henley Ion Inc. is encouraged by early testing of a COVID-19 protection device. Henley’s Ion Virus Defender technology uses micronized electrostatic precipitation (mEP) to remove infectious bioaerosols from both inhaled and exhaled air. The company said initial tests of the prototype removed 99.8% of SARS-CoV-2 bioaerosols under Biosafety Level 3 testing conditions.
Read More
Pills spilling out of prescription bottle

Everest acquires rights to 3CL protease inhibitors to develop antivirals for COVID-19

Jan. 14, 2022
By David Ho
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.
Read More
Patrick Doyle, CEO, Kbio Holdings Ltd.
Newco news

BAT follows tobacco rival Philip Morris into biotech, promising faster R&D with Kbio’s plant-based tech

Jan. 14, 2022
By Richard Staines
Following Philip Morris International Inc.’s controversial takeover of respiratory drug firm Vectura plc, British American Tobacco plc (BAT) is also making inroads into medical research with U.K.-based Kbio Holdings Ltd., a biotech focused on plant-based medicine.
Read More

In the clinic for Jan. 14, 2022

Jan. 14, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adagene, AI, Ascletis, First Wave, Gritstone, GSK, Imcyse, Oncopeptides, On Target, Redhill, Rhythm, Rubius, Spago, Tempus.
Read More
U.S. flag and White House podium

Biden administration boosts at-home COVID-19 test purchase to 1B

Jan. 13, 2022
By Annette Boyle
In a speech on Jan. 13, President Joe Biden revealed plans to purchase an additional 500 million at-home COVID-19 tests, bringing the total number the administration expects to provide for free to American households to 1 billion. In addition, Biden said the administration would distribute free “high quality masks.” On Wednesday, the administration said it would provide 5 million rapid COVID-19 tests and 5 million lab-based PCR tests to schools each month to support screening testing and test-to-stay programs.
Read More
Previous 1 2 … 142 143 144 145 146 147 148 149 150 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 18, 2026.
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • Doctor with brain illustration, businessman with dollar sign illustration

    Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

    BioWorld
    Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
  • Illustration of tau accumulating in a neuron cell.

    Biogen AD drug shows tau, cognition benefit, despite trial miss

    BioWorld
    Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing